Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
A phase II study to assess the efficacy and safety of Fruquintinib Combined With Sintilimab
and Chemotherapy as a first-line treatment in patients with unresectable or metastatic
advanced Wild-type Genotype non-squamous Non-small Cell Lung Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University